CCR4/CD194 Full-Length Membrane Proteins, Antibodies and Stable Cell Lines

C-C Chemokine Receptor 4 (CCR4), also known as CD194 or CMKBR4, is a class A chemokine receptor whose major ligands include CCL17 and CCL22. It is expressed on Th2 cells, regulatory T cells, and selected skin-homing T-cell populations and regulates immune-cell trafficking through Gi-dependent chemotactic signaling. The CCR4-CCL17/CCL22 pathway is strongly associated with Th2-type inflammation and immune-cell recruitment in allergic and inflammatory disease. CCR4 is also highly expressed in selected T-cell malignancies, while CCR4-positive regulatory T cells can contribute to immune suppression within the tumor microenvironment. These dual roles make CCR4 relevant both as a direct cell-surface target and as a mechanism for modulating tumor-associated Tregs.

DIMA BIOTECH provides multiple full-length human CCR4 membrane-protein formats, including Nanodisc and cell-free preparations, for native GPCR antibody discovery, SPR/BLI, binding analysis, and specificity assessment. Human, mouse, and cynomolgus extracellular/N-terminal proteins support ELISA, epitope analysis, and cross-species evaluation. Flow cytometry-validated monoclonal antibodies, reference antibodies, and conjugated formats support cell-surface detection and candidate benchmarking. A CCR4-overexpressing stable cell line provides a standardized platform for FACS, cell-binding studies, and cellular antibody screening. In addition, to accelerate the development of CCR4 biotherapy, DIMA BIOTECH has also prepared a single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CCR4 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.